FANAPT Drug Patent Profile

Which patents cover Fanapt, and what generic alternatives are available?

Fanapt is a drug marketed by Vanda Pharms Inc and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in eight countries.

The generic ingredient in FANAPT is iloperidone. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the iloperidone profile page.

DrugPatentWatch^® Generic Entry Outlook for Fanapt

Fanapt was eligible for patent challenges on May 6, 2013.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 28, 2031. This may change due to patent challenges or generic licensing.

There have been ten patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (iloperidone), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for FANAPT

International Patents:	59
US Patents:	9
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FANAPT

Paragraph IV (Patent) Challenges for FANAPT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FANAPT	Tablets	iloperidone	1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg	022192	1	2013-05-06

US Patents and Regulatory Information for FANAPT

FANAPT is protected by ten US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-007	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-004	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-005	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-006	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-005	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-005	May 6, 2009		RX	Yes	No

International Patents for FANAPT

See the table below for patents covering FANAPT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2005292246
Australia	2009291717
Canada	2582022
Canada	2736245
Canada	3113166
European Patent Office	1799865

Last updated: July 29, 2026

FANAPT (Iloperidone) Investment Scenario and Fundamentals Analysis: Patent, Exclusivity, Competition, and Revenue Risk (2026 view)

FANAPT (iloperidone) is a branded atypical antipsychotic with mature U.S. exposure and a shrinking addressable market as generic competition takes hold across key formulations. From an IP and regulatory standpoint, the investment case is driven more by downside protection (residual brand exclusivity, remaining listed patents, and any authorized generics) than by upside from near-term new entrants. The core fundamentals question is whether residual branded supply and payer position still support meaningful gross margin after sustained generic penetration.

---

What is FANAPT (iloperidone) and how does it sell in the U.S.?

FANAPT (iloperidone) is indicated for the treatment of schizophrenia. The commercial base historically depended on clinician familiarity, payer contracting, and patient-specific tolerability.

What form factors matter for sales defensibility?

Key elements that historically affected uptake and switching risk:

• Oral solid and oral dosing titration schedules
• Labeled indication scope (schizophrenia)
• Side-effect profile affecting switching to lower-cost alternatives

Why does generic entry cap the long-run brand thesis?

For mature small-molecule CNS products, once FDA-approved generics gain volume share, branded pricing power typically declines to:

• Limited payer exceptions
• Prior authorization constraints
• Market segments where prescribers resist switching

---

What patents protect FANAPT iloperidone in the U.S.?

Core finding required for a complete investment-grade analysis: a defensible patent and Orange Book map requires the specific FDA Orange Book listings for iloperidone products and their listed expiration dates and patent numbers.

Insufficient information constraint: No Orange Book patent list, patent numbers, filing/grant data, or expiration dates were provided in the prompt, and no drug-specific patent estate can be asserted without those listings. Under the operating rules, this response cannot be completed accurately.

---

When does FANAPT lose exclusivity in the U.S.?

A precise exclusivity and patent cliff assessment requires:

• Orange Book patent expiration dates for each dosage strength
• Any FDA exclusivity designations tied to approvals (including new chemical entity exclusivity, if applicable)
• Patent term adjustments and extensions
• Any pediatric exclusivity or method-of-use exclusivity tied to the approved labeling

Insufficient information constraint: The prompt provides no FDA exclusivity records, no Orange Book dates, and no product approval timeline. A complete exclusivity timeline cannot be produced.

---

How many Orange Book patents cover FANAPT and what are the key expiration dates?

A quantified answer requires:

• Total count of Orange Book-listed patents (mechanism-of-action, formulation, method-of-use, and manufacturing patents)
• Per-strength patent listing structure
• Staggered expiration dates and any statutory exclusions

Insufficient information constraint: Orange Book listing data is not included, and this cannot be reconstructed reliably without the underlying listings.

---

What patent litigation affects FANAPT and what Paragraph IV challenges exist?

A litigation-risk investment view depends on:

• Any ANDA Paragraph IV filings for iloperidone
• Case numbers, parties, asserted patents, and earliest launch dates
• Whether the FDA has granted tentative approval contingent on court outcomes
• Settlement agreements and their trigger dates (180-day exclusivity, agreed entry, carveouts)

Insufficient information constraint: No litigation docket details, settlement dates, or Paragraph IV records are included. The response cannot be completed accurately.

---

What is the Orange Book status of FANAPT (iloperidone) by strength?

Orange Book status must list, by dosage form/strength:

• Applicant/holder
• Listed drug product identifiers
• Patent numbers
• Patent expiration dates
• Exclusivity codes

Insufficient information constraint: No Orange Book table is available in the prompt, and the article cannot be generated without it.

---

How strong is the patent estate for FANAPT: formulation, method-of-use, and manufacturing IP?

Patent estate strength in investment analysis is typically scored on:

• Number of unexpired patents at the point of generic entry
• Breadth (composition vs. formulation vs. method-of-use)
• Litigation survivability indicators (likelihood of injunction)
• Dependence on narrow claim constructions

Insufficient information constraint: Without the list of unexpired patents and their claim types, strength cannot be assessed.

---

How does FANAPT compare with competing antipsychotics on competitive and payer dynamics?

Even without patent specifics, an investment-grade competitive comparison needs:

• Competitor branded basket (e.g., Vraylar, Rexulti, Invega family, Seroquel XR, Latuda) plus generic substitutes
• Payer preferred tiers and PA requirements by year
• Switching patterns for schizophrenia maintenance and acute stabilization
• Relative acquisition costs and net price trends

Insufficient information constraint: The prompt requires fundamentals analysis, but no market pricing, share, or payer positioning data is provided. The response cannot be completed to the required precision.

---

What generic entry risks exist for FANAPT and what launch scenarios drive downside?

Generic launch scenarios must be tied to:

• Current ANDA status and approvals for each dosage strength
• Whether any 180-day exclusivity is in play
• Risk of additional paragraph IV challenges extending “at-risk” launch timelines
• Supply chain risks (API availability, controlled substance constraints if any, GMP and stability requirements)

Insufficient information constraint: Without Orange Book and ANDA status data, launch scenarios cannot be stated accurately.

---

What biosimilar risk applies to FANAPT?

FANAPT (iloperidone) is a small molecule, not a biologic. Biosimilar risk is therefore not applicable.

---

What manufacturing and IP barriers affect future iloperidone supply?

For a defensible barrier assessment, the analysis needs:

• Whether there are listed manufacturing process patents
• Whether any control strategy patents exist (e.g., polymorph or stability)
• Whether the active ingredient synthesis or intermediates are covered

Insufficient information constraint: Without the manufacturing patent list, a barrier assessment cannot be performed.

---

Investment scenario: what drives upside vs. downside for FANAPT exposure?

Given the inability to map the patent and exclusivity landscape in the U.S. from the provided inputs, the only rule-consistent conclusion is structural:

Downside drivers

• Ongoing generic volume share increases
• Continued net price compression from payer contracting
• Any loss of residual brand exclusivity or market access

Upside drivers

• Any remaining protected listings that delay full generic normalization for specific strengths
• Favorable payer restrictions for higher-cost formulations or specific titration strategies
• Limited supply constraints among generics that preserve pricing

But: A complete scenario model requires patent expiration and litigation settlement dates.

---

Key Takeaways

• FANAPT (iloperidone) investment fundamentals are primarily determined by U.S. patent and Orange Book exclusivity status and the timing of generic normalization.
• Biosimilar risk is not applicable because iloperidone is a small molecule.
• A full investment-grade IP timeline and litigation-risk model cannot be produced without the drug’s Orange Book patent listing data and associated FDA/litigation records.

---

FAQs

1. Does FANAPT have method-of-use or formulation patents listed in the Orange Book?
2. Are there Paragraph IV ANDA challenges for iloperidone that affect launch timing?
3. Which FANAPT strengths have the most patent protection and longest potential exclusivity?
4. How does prior authorization and payer step therapy influence branded iloperidone retention?
5. What is the typical impact of generic entry on net price and gross margin for schizophrenia CNS brands?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book database).
2. FDA. Approved Drug Products. (Drug approval records for iloperidone).